Shots:

• The approval is based on the two P-III clinical trials i.e EMERGE and ENGAGE along with P-Ib PRIME study involves assessing the efficacy of Aduhelm vs PBO in patients with early stages of AD with confirmed presence of amyloid pathology
• Results: the therapy consistently showed a dose and time-dependent effect on the reduction of amyloid-beta plaques by 59 % in ENGAGE- 71% in EMERGE- and 61% in PRIME- reduction in clinical decline- and well-characterized safety profile in ~ 3-000 patients who received at least one dose of Aduhelm
• Biogen will conduct a controlled trial to verify the clinical benefit of the therapy in patients with AD

Ref: Business Wire | Image: Biogen